Inhaled combination therapies for pulmonary fibrosis

Proprietary dry-powder inhaled therapies for pulmonary fibrosis and interstitial lung disease, built on the SPRAYE™ platform.

The SPRAYE™ platform

SPRAYE™ is a dry-powder inhalation approach built around engineered particles. The aim is to put two active ingredients into the deep lung in one puff, in a small single-use device.

Two activeingredientsOne engineeredparticleOne puff from adisposable inhalerDeep lung
Illustrative schematic, not to scale. Design intent for investigational programs.
Format
Dry-powder inhaler, pocket-sized, disposable
Delivery target
Deep lung
Approach
Fixed-dose combinations in a single puff
Focus
Pulmonary fibrosis and interstitial lung disease

Compared with oral or nebulized regimens, the intended advantages are improved pulmonary exposure, tolerability, adherence and convenience. These are design goals and potential benefits, not demonstrated clinical results.